Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 63.5637
0.799 %
$ 14.2 B
Market Cap
26.5
P/E
1. INTRINSIC VALUE
Balance Sheet
Hologic, Inc.
| Current Assets | 3.82 B |
| Cash & Short-Term Investments | 2.33 B |
| Receivables | 600 M |
| Other Current Assets | 889 M |
| Non-Current Assets | 5.33 B |
| Long-Term Investments | 151 M |
| PP&E | 630 M |
| Other Non-Current Assets | 4.55 B |
| Current Liabilities | 1.04 B |
| Accounts Payable | 204 M |
| Short-Term Debt | 64.8 M |
| Other Current Liabilities | 769 M |
| Non-Current Liabilities | 2.99 B |
| Long-Term Debt | 2.59 B |
| Other Non-Current Liabilities | 396 M |
EFFICIENCY
Earnings Waterfall
Hologic, Inc.
| Revenue | 4.03 B |
| Cost Of Revenue | 1.8 B |
| Gross Profit | 2.23 B |
| Operating Expenses | 1.35 B |
| Operating Income | 970 M |
| Other Expenses | 181 M |
| Net Income | 790 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Hologic, Inc.
| Net Income | 790 M |
| Depreciation & Amortization | 309 M |
| Capital Expenditures | -140 M |
| Stock-Based Compensation | 82.3 M |
| Change in Working Capital | 84.1 M |
| Others | 161 M |
| Free Cash Flow | 1.14 B |
Wall Street Analysts Price Targets
Hologic, Inc.
Wall Street analysts predict an average 1-year price target for HOLX of $75.1 , with forecasts ranging from
a
low of
$33 to a high of $90 .
HOLX Lowest Price Target
Wall Street Target
33 USD
-48.08%
HOLX Average Price Target
Wall Street Target
75.1 USD
18.22%
HOLX Highest Price Target
Wall Street Target
90 USD
41.59%
4. DIVIDEND
ANALYSIS
HOLX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Hologic, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.9 M USD 1
9-12 MONTHS
9.31 M USD 5
Bought
301 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
zacks.com
- 2 weeks ago
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
ARLINGTON, Va.--(BUSINESS WIRE)--NEST, an initiative of MDIC, is pleased to welcome Hologic, a leading global medical device company, to its Governance Committee.
businesswire.com
- 2 weeks ago
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
zacks.com
- 2 weeks ago
Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?
Private equity firms TPG and Blackstone BX recently bid to acquire Hologic Inc. HOLX, valuing the U.S. medical technology company at over $16 billion.
benzinga.com
- 3 weeks ago
Hologic reportedly rejects $16B go-private offer from TPG, Blackstone
TPG and Blackstone Inc (NYSE:BX), two private equity firms, have made a non-binding offer of more than $16 billion to take medical equipment-maker Hologic Inc (NASDAQ:HOLX) private, according to a media report from the Financial Times. Citing people with knowledge of the matter, the publication said Massachusetts-based Hologic has rejected the offer.
proactiveinvestors.com
- 3 weeks ago
Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports
Medical equipment maker Hologic rejected a $16 billion non-binding offer from private equity firms TPG and Blackstone , the Financial Times reported on Tuesday, citing people familiar with the matter.
reuters.com
- 3 weeks ago
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more.
zacks.com
- 3 weeks ago
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test.
businesswire.com
- 3 weeks ago
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
zacks.com
- 1 month ago
Hologic to Webcast Presentations at Upcoming Investor Conferences
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentations at Upcoming Investor Conferences.
businesswire.com
- 1 month ago
Understanding Hologic (HOLX) Reliance on International Revenue
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
zacks.com
- 1 month ago
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance.
zacks.com
- 1 month ago
8. Profile
Summary
Hologic, Inc. HOLX
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 14.2 B
Dividend Yield
0.00%
Description
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Contact
250 Campus Drive, Marlborough, MA, 01752
https://www.hologic.com
IPO
Date
March 1, 1990
Employees
7063
Officers
Ms. Monica Aguirre Berthelot
Vice President & Chief of Staff
Ms. Karleen M. Oberton CPA
Chief Financial Officer
Mr. Stephen P. MacMillan
Chairman, Chief Executive Officer & President
Ms. Anne Liddy
General Counsel
Mr. Paul Malenchini
Chief Information Officer
Dr. Jennifer M. Schneiders Ph.D.
Division President of Diagnostic Solutions
Mr. Jan Verstreken
Group President of International
Ms. Diana De Walt SPHR
Senior Vice President of Global Human Resources
Mr. Essex D. Mitchell
Chief Operating Officer
Mr. Michael J. Watts
Corporate Vice President of Investor Relations